The Pharma Perspective

6 Episodes

Reverse

Rethinking Medications: From Academic Detailing to Broken Drug Regulation | Jerry Avorn | EP 6

2026-01-1501:05:23

In this episode of The Pharma Perspective podcast, Jerry Avorn, Professor of Medicine at Harvard Medical School and author of "Rethinking Medications," discusses the state of drug regulation in the United States, the problems with accelerated approvals and missing confirmatory trials, how academic detailing can change prescribing behavior more effectively than guidelines, the misuse of surrogate endpoints in drug development, why weak FDA enforcement actually harms pharmaceutical innovation, the absence of cost-effectiveness analysis and health technology assessment in US drug policy, and where he sees hope for reform through state-level drug policy coalitions and evidence-based prescribing initiatives.

Measuring What Patients Actually Care About | Katja Rüdell | EP 5

2026-01-1501:15:14

In this episode of The Pharma Perspective podcast, Katja Rüdell, one of the world's leading clinical outcome assessment and patient-reported outcomes experts, discusses the role of PROs in drug development, regulatory expectations from FDA and EMA for outcome measure validation, the challenges of developing fit-for-purpose COA instruments, the evolution of patient-centred research in pharmaceutical clinical trials, and best practices for ensuring PRO data meets both regulatory and clinical standards.

What Does the ABPI Actually Do? | Jack Neill-Hall | EP 4

2025-12-0737:07

In this episode of The Pharma Perspective podcast, Jack Neill-Hall from the Association of the British Pharmaceutical Industry (ABPI) discusses the UK pharmaceutical pricing environment, NICE's cost-effectiveness threshold and appraisal process for NHS medicines, industry transparency through the Code of Practice and Disclosure UK, healthcare budget allocation, and why some medicines never reach UK assessment.

Is Raising the NICE Threshold Bad for NHS Patients? | Karl Claxton | EP 3

2025-12-0753:30

In this episode of "The Pharma Perspective", I speak with Karl Claxton, Professor of Economics at the University of York and founding NICE Appraisal Committee member, about his open letter to the UK Prime Minister on pharmaceutical pricing for branded medicines, why raising the NICE willingness-to-pay threshold would be catastrophic for NHS patients, and his proposals for fundamentally reforming health technology assessment and how we value pharmaceutical innovation. 💷🏥

Starting a Pharma Consultancy in a Pandemic: The PharmacoEvidence Story | Barinder Singh | EP 2

2025-10-2801:11:57

Join me in my discussion with Barinder Singh, Founder of PharmacoEvidence, who quit his stable HEOR job in 2020—amid a pandemic and with a baby on the way—to start his own consultancy. In this episode of The Pharma Perspective, we explore how that bold decision turned into a thriving 40+ person company leading NICE submissions with AI-validated methods. We also talk about what it really takes to build an HEOR consultancy, the subjectivity in NICE appraisals, and how AI is reshaping evidence synthesis. A conversation about timing, risk, and self-awareness you won't want to miss.

How to Build a Meaningful Pharma Career – Leadership Lessons from a GM | Peter Wickersham | EP 1

2025-08-1750:39

Join me in my discussion with Peter Wickersham, Pharma Vice President & General Manager with 25+ years of experience, as we explore leadership, career growth, and navigating the evolving pharma industry in the age of AI. In this episode of Pharma Perspectives, Peter shares his insights on the challenges and opportunities shaping pharma today, offering practical advice for professionals interested in health economics, strategy, and the future of healthcare. Whether you're a healthcare professional, consultant, or simply curious about how the pharma world works behind the scenes, this conversation is packed with actionable insights and thought-provoking ideas.

#box-pro-ellipsis-177186266631833{-webkit-line-clamp:2;}The Pharma Perspective